AbstractBySubCategory

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
Intermediate-term outcomes from the DISSRM registry: A prospective analysis of active surveillance in patients with small renal masses. Ridwan Alam

430

A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). David F. McDermott

431

Comparative effectiveness of tumor response assessment methods: Standard-of-care versus computer-assisted response evaluation. Brian Allen

432

Cryoablation of cT1 renal masses in the “healthy” patient: Early outcomes from Mayo Clinic. Harras B. Zaid

433

Evolution of circulating tumor DNA (ctDNA) profile from first-line (1L) to second-line (2L) therapy in metastatic renal cell carcinoma (mRCC). Sumanta K. Pal

434

Changes in tumor burden and IMDC class after active surveillance (AS) for metastatic renal cell carcinoma (mRCC). Davide Bimbatti

435

A single-arm biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer (PRCC). Toni K. Choueiri

436

Single-nucleotide polymorphisms (SNPs) associated with outcomes in patients with localized and metastatic renal cell carcinoma (RCC). Carmen Garrigos

437

Patients with metastatic renal cell carcinoma who have benefit from axitinib dose titration: Analysis from a randomized, double-blind, axitinib dose titration phase II study. Yoshihiko Tomita

438

Expression of tyrosine kinase AXL receptor in patients with metastatic renal cell carcinoma treated with sunitinib and its association with clinical and pathological outcomes. Luis Eduardo Rosa Zucca

439

Safety and preliminary activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma (mRCC): A cytokine working group study. Leonard Joseph Appleman

440

Comparison of different prognostic scores versus physician’s subjective prognosis in patients with advanced/metastatic renal cell carcinoma treated with temsirolimus in regular clinical setting: An analysis of the STAR-TOR registry. Martin Boegemann

441

Correlation of insulin-receptor expression with efficacy of axitinib in patients with advanced renal cell carcinoma. Masayuki Takahashi

442

The association between age-related macular degeneration (AMD) and renal cell carcinoma (RCC): A nested case-control study. Daniel Keizman

443

Intra-individual genomic diversity between circulating tumor cell-free DNA (cfDNA) and tumor tissue testing in metastatic renal cell carcinoma (mRCC). Andrew W. Hahn

444

Development of a novel patient-derived preclinical model from malignant effusions in patients with tyrosine kinase inhibitor resistant clear cell renal cell carcinoma. Jung Hun Kang

445

Effect of benign and tumor parenchyma metabolomic profiles on compensatory renal growth in renal cell carcinoma surgical patients. Barak Rosenzweig

446

Cabozantinib (C) exposure-response (ER) modeling of safety endpoints in patients (pts) with renal cell carcinoma (RCC) in the phase III METEOR study. Steven Lacy

447

The impact of UGT1A1 and SLCO1B1 genetic polymorphisms and pharmacokinetics of axitinib on clinical safety and efficacy in patients with metastatic renal cell carcinoma. Shintaro Narita

448

Impact of obesity and adiponectin signaling in patients with renal cell carcinoma: A potential mechanism for the obesity paradox. Shintaro Narita

449

Combined inhibition of autophagy with mTOR inhibitor to enhance cell death in renal cell carcinoma. Hua Chen

450

IVOIRE: Results of a prospective multicentre cohort study in advanced renal carcinoma. Eric Voog

451

An evaluation of abemaciclib activity in combination with sunitinib in renal cell carcinoma. Sheldon L. Holder

452

Neutrophil lymphocyte ratio (NLR) as a clinical biomarker predictive of outcomes with immune checkpoint inhibitor therapy in genitourinary cancers. Ghayathri Jeyakumar

453

Effect of NKTR-214 on the number and activity of CD8+ tumor infiltrating lymphocytes in patients with advanced renal cell carcinoma. Michael E. Hurwitz

454

Development of a prognostic nomogram for liver toxicity in patients treated with pazopanib. Michael W. Kattan

455

Clinicopathologic characterization and outcomes for patients with renal medullary carcinoma: Results from the National Cancer Database. Harras B. Zaid

456

Dose adjustment of axitinib based on AUC in sunitinib-pretreated metastatic renal cell carcinoma. Yuji Miura

457

Sunitinib dose escalation after disease progression in metastatic renal cell carcinoma. Jacques Raphael

458

Meta-analysis of disease free survival (DFS) as a surrogate for overall survival (OS) in localized renal cell carcinoma (RCC). Lauren Christine Harshman

459

Addressing metabolic heterogeneity in clear cell renal cell carcinoma with quantitative magnetic resonance imaging. Ivan Pedrosa

460

Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Lisa Derosa

462

Prognosis of renal cell carcinoma with bone metastases: Experience in 300 consecutive patients. Fiorella Ruatta

463

A novel strategy for axitinib dosing in the treatment of metastatic renal cell carcinoma. Gary Doherty

464

Eligibility criteria and endpoints in metastatic renal cell carcinoma trials. Sarah Wong

465

An exploratory study of radium-223 and vascular endothelial growth factor targeted therapy (VEGF TT) in patients (pts) with metastatic renal cell carcinoma (mRCC) and bone metastases (BM). Rana R. McKay

466

Outcomes of PD-1/PD-L1 responders who discontinue therapy for immune-related adverse events (irAEs): Results of a cohort of patients (pts) with metastatic renal cell carcinoma (mRCC). Rana R. McKay

467

Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). Naveen S. Basappa

468

Sunitinib versus sorafenib as first-line therapy followed by sorefenib and sunitinib for patients with metastatic renal cell carcinoma (RCC) with clear cell histology: A multicenter randomized trial, CROSS-J-RCC. Yoshihiko Tomita

469

The role of microRNAs (miRNAs) as predictive biomarker in advanced renal cell carcinoma (mRCC) patients (pts) with “extreme response” to tyrosine kinase inhibitors (TKIs) treatment. Carmen Garrigos

470

Effects of change in surgical approach in T3 renal cell carcinoma (RCC) with intracaval thrombus on complications and survival. Marleen Suzanne Vallinga

471

T cell infiltration in matched renal biopsy (bx) and nephrectomy (nx) samples in renal cell carcinoma (RCC). Haris Zahoor

472

The SUNPAZ study: Results of an open label, single arm trial to evaluate patients with mRCC treated with everolimus after failure of first line therapy with sunitinib or pazopanib. Martin Schostak

473

The genomic landscape of metastatic non-clear cell renal cell carcinoma. Maria Isabel Carlo

474

Real-world economic outcomes among patients (pts) who initiated sunitinib or pazopanib as first targeted therapy (TT) for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data. Nicholas J. Vogelzang

475

The efficacy and safety in elderly patients with advanced renal cell carcinoma: Real-world use of sorafenib in Japan. Katsunori Tatsugami

476

Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8+ T cells on clinical benefit from PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC). Jean-Christophe Pignon

477

Cabozantinib for the treatment of patients with metastatic variant histology renal cell carcinoma (vhRCC): A retrospective study. Matthew T. Campbell

478

Epigenetic targeting of clear cell renal cell carcinoma (ccRCC) with ascorbic acid (AA) via upregulation of Ten-Eleven Translocation (TET) methylcytosine dioxygenase activity. Niraj Konchady Shenoy

479

CHEK2 mutation in renal cell carcinoma (RCC): Single center experience. Joanna Huszno

480

Effect of nivolumab on tumor growth rate (TGR) in metastatic renal cell carcinoma (mRCC). Camille Mazza

481

Clinical activity of PD1/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC). Raphael Brandao Moreira

482

Intraoperative conversion from partial to radical nephrectomy: Predictive factors and outcomes. Firas G. Petros

483

Tumor genomic analysis for 128 renal cell carcinoma (RCC) patients receiving first-line everolimus: Correlation between outcome and mutations status in MTOR, TSC1, and TSC2. Martin Henner Voss

484

ABCB1, CYP3A5*3, and CYP3A4*1B SNPs and risk of toxicity with sunitinib treatment for mRCC. Maria Bassanelli

485

Determinants of treatment in patients with stage IV renal cell carcinoma. Christopher S. Hollenbeak

486

Health-related quality of life (HRQoL), treatment satisfaction, and work productivity for patients (Pts) with advanced renal cell carcinoma (aRCC) in a chart review across six countries. Robert Hawkins

487

Is RECIST-defined progression free-survival a meaningful endpoint in the era of immunotherapy? Sukhvinder Johal

488

Long term overall survival (OS) in patients with primary metastatic kidney cancer: An analysis of 1468 patients from the Austrian National Cancer Registry (ANCR). Martin Marszalek

489

BAP1 tumor predisposition syndrome: Preliminary data from a laboratory-based multigene panel testing cohort. Carrie Horton

490

Impact of rural/urban residence on relative survival (RS) in patients with kidney cancer: An analysis of 14576 patients from the Austrian National Cancer Registry (ANCR). Martin Marszalek

491

Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC. Steven Yip

492

Proton pump inhibitors (PPIs) and survival outcomes in patients with metastatic renal cell carcinoma (mRCC). Aly-Khan A. Lalani

493

Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in mRCC patients treated with immune-checkpoint inhibitors. Melissa Bersanelli

494

Second line axitinib in metastatic renal cell carcinoma: Evaluation of prognostic factors influencing outcome. Helen Brooks

495

Do CT perfusion measures predict early clinical response in patients with advanced renal cell carcinoma? Alice C. Fan

496

Management of renal masses in an octogenarian cohort: Is there a right approach? Jude Nawlo

497

Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Igor Stukalin

498

The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy. Dipesh Uprety

499

Whole blood mRNA expression for prognosis of metastatic clear cell renal carcinoma (mCCRCC). Karthik Giridhar

500

Litmus test or destination systemic therapy? Trends in referral for surgery after initial systemic therapy in metastatic kidney cancer. Liam Connor Macleod

502

Impact of cytoreductive nephretomy on timing of systemic therapy in metastatic kidney cancer. Liam Connor Macleod

503

Pattern of glycosylphosphatidylinositol-anchored 80 kD protein (GPI-80) expression in peripheral blood as a marker for myeloid-derived suppressor cells (MDSCs) in metastatic renal cell cancer (mRCC) patients. Tomoyuki Kato

504

Ablative therapy to induce local and systemic immune changes in patients with metastatic renal cell carcinoma. Matthew T. Campbell

505

Impact of pharmacokinetics (PK) of sunitinib (SU) and its metabolite SU12662 on clinical outcome and toxicity in metastatic renal cell cancer (mRCC) patients. Nicolas Martin

506

Perinephric white adipose tissue inflammation in clear cell renal cell carcinoma (ccRCC). Helena Furberg

507

Correlation between inflammatory markers in blood and expression of costimulatory molecules on tumor-infiltrating CD8+ lymphocytes in renal cell carcinoma. Haydn T. Kissick

508

Predictors of mortality in metastatic papillary renal cell cancer. Abhinav Sidana

509

Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC): Phase 1 KEYNOTE-029 study. Toni K. Choueiri

510

Immune cell phenotyping of clear cell renal cell carcinoma. Mazyar Ghanaat

511

Does dose modification affect efficacy of first-line pazopanib in metastatic renal cell carcinoma? Paolo Grassi

512

Genomic profiling of nephrectomy and metastatic sites in patients with advanced clear cell renal cell carcinoma (RCC). Guillermo de Velasco

513

Meta-analysis of upfront VEGF targeted therapy prior to nephrectomy in metastatic clear cell renal cancer. Akhila Ganeshi Wimalasingham

514

Characterization of patients (pts) with poor risk metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database. Lana Hamieh

515

DNA methylation signature for the assessment of metastatic risk in primary renal cell cancer. Inga Peters

516

Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in patients with advanced renal cell carcinoma (RCC). Frede Donskov

517

An exploratory study to investigate the immunomodulatory activity of radiation therapy in combination with pembrolizumab in patients with renal cell cancer. Jianqing Lin

518

Categorization of gene expression subtypes in clear cell renal cell carcinoma with sarcomatoid features. Shreyas Joshi

519

Brain metastases (BM) from renal cell carcinoma treated with nivolumab: Evidence of early brain flare? Laurence Albiges

520

Use of liquid biopsy for detection of renal cell carcinoma. Dean Laganosky

521

Analysis of overall survival (OS) based on tumor target lesion change in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC). Sumanta K. Pal

522

Retrospective review of cytotoxic chemotherapy and anti-angiogenic combinations in renal cell carcinoma: A single institution experience. Bradley Curtis Carthon

523

Predictors of long-term responders in patients treated with pazopanib for advanced renal cell carcinoma (aRCC). Jinhee Park

524

Analysis of predictive clinical markers of outcome in patients with metastatic clear-cell renal cell carcinoma (mRCC) treated with tyrosine-kinases inhibitors (TKI) in first line: A C Camargo Cancer Center experience. Camila Nassif Martins Ferreira

525

Beyond classical risk adjustment: Socioeconomic status and hospital performance in urologic oncology. Anobel Y. Odisho

526

CLOVIZ: Clinical outcomes visualization of IMDC criteria in metastatic renal cell carcinoma for patient-centered decision making. Anobel Y. Odisho

527

A phase 1 study of alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma immunotherapy in patients with metastatic renal cell cancer. Hans J. Hammers

528

Contemporary incidence and epidemiologic trends of brain metastases at renal cell carcinoma diagnosis. Maxine Sun

529

Biomarker study of early death in patients with intermediate and favorable risk metastatic renal cell carcinoma. Wayne Harris

530

Cryotherapy and thermal ablation for renal malignancy over 3cm: Comparative analysis of survival with small renal masses. Alex Jones

531

Additive prognostic impact of elevated De Ritis ratio and renal score in predication of survival outcomes in localized renal cell carcinoma. Zachary Hamilton

532

A phase II study of alternative sunitinib scheduling in patients with metastatic renal cell carcinoma. Eric Jonasch

533

Outcomes of patients (pts) with renal cell carcinoma and sarcomatoid dedifferentiation (sRCC) treated with nephrectomy (Nx) and systemic therapies (T) over three decades: The MD Anderson Cancer Center (MDACC) experience. Sarp K. Keskin

534

Pathological determinants of oncologic outcomes in stage II renal cell carcinoma: An international multicenter analysis. Zachary Hamilton

535